American biotech company Guardant Health is transforming the global cancer diagnosis market with its liquid biopsy technology that diagnoses cancer with "a single drop of blood." The company has secured 100 million subscribers through an expanded insurance coverage by UnitedHealth earlier this month, with its stock price soaring 53% since the beginning of 2026, raising expectations for commercial success to an all-time high.
The liquid biopsy technology developed by Guardant Health is evaluated as an innovative technology that overcomes the limitations of conventional invasive cancer diagnosis methods. Founded in 2012 by co-CEOs Helmy Eltoukhy and Amiralii Talasaz and listed on NASDAQ in 2018, the company uses next-generation sequencing (NGS) analysis to detect trace amounts of cancer cell DNA fragments in blood to diagnose and monitor cancer. On July 17, 2026 (local time), Guardant Health's stock closed at $155.87 on the New York Stock Exchange, surging 53.2% since the beginning of this year. Bank of America Securities raised its target stock price for the company by 40%, from $135 to $190, reflecting high market expectations.
Guardant Health's liquid biopsy technology has the advantage of diagnosing cancer and monitoring its progression with a simple blood draw instead of painful and invasive tissue biopsy. This significantly improves patient convenience and expands the potential for early cancer diagnosis. Major services include "Guardant360," which helps personalize cancer drug prescriptions; "Guardant Shield," for early detection of colorectal cancer; and "Guardant Reveal," a recurrence prevention monitoring service. The company is also building a diverse revenue model through companion diagnostic collaborations with various pharmaceutical companies.
This innovative technology is leading to steep improvements in performance. Guardant Health recorded revenue of $301.7 million in the first quarter of 2026, a 48% increase compared to the same period last year, exceeding market expectations. Earnings per share (EPS) was negative $0.45, significantly reducing the loss margin compared to market expectations (negative $0.78), raising expectations for improved profitability. The company raised its annual revenue outlook from $1.25 billion to $1.28 billion to $1.30 billion to $1.32 billion, demonstrating confidence in its growth trajectory.
